Please enable Javascript
Matthew Campbell, MD, MS
Matthew Campbell, MD, MS, University of Texas MD Anderson Cancer Center
Articles by Matthew Campbell, MD, MS
Navigating Refractory RCC: Sequencing, Combinations, and Emerging Therapies
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
February 25, 2025
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
View More
Cytoreductive Nephrectomy and RCC Biomarkers: What’s Next in Kidney Cancer Treatment?
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
February 25, 2025
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
View More
Triplet Therapy in RCC: Insights from ASCO GU 2025
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
February 25, 2025
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
View More
The Future of Adjuvant Treatment for RCC: Biomarkers, Trial Data, and Clinical Challenges
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
February 25, 2025
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
View More
Adjuvant Therapy in Kidney Cancer: Patient Selection and Evolving Strategies
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
February 25, 2025
Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits.
View More
UNITE Study: Outcomes With SG for Patients with Variant Histologies
Vadim Koshkin, MD
Urothelial Carcinoma
|
February 12, 2024
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
View More
UNITE Study: Sequencing Erdafitinib and EV for Patients With FGFR2/3-Altered Disease
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 20, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
View More
UNITE Study: Impact of Squamous, Other Histologies on Outcomes With EV
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 20, 2024
The impact of squamous and other histologies on outcomes with EV are dissected.
View More
UNITE Study: Design, Patients Sampled, and Outcomes With EV After Switch Maintenance Avelumab
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 20, 2024
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
View More